BIOMAT Database Logo BIOMAT Database Logo

Phase II evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with non-small cell lung cancer. 1980

E S Casper, and R J Gralla, and D P Kelsen, and R B Natale, and P Sordillo, and A Houghton

UI MeSH Term Description Entries
D007970 Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000). Leukocytopenia,Leukocytopenias,Leukopenias
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D002277 Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for "cancer." Carcinoma, Anaplastic,Carcinoma, Spindle-Cell,Carcinoma, Undifferentiated,Carcinomatosis,Epithelial Neoplasms, Malignant,Epithelioma,Epithelial Tumors, Malignant,Malignant Epithelial Neoplasms,Neoplasms, Malignant Epithelial,Anaplastic Carcinoma,Anaplastic Carcinomas,Carcinoma, Spindle Cell,Carcinomas,Carcinomatoses,Epithelial Neoplasm, Malignant,Epithelial Tumor, Malignant,Epitheliomas,Malignant Epithelial Neoplasm,Malignant Epithelial Tumor,Malignant Epithelial Tumors,Neoplasm, Malignant Epithelial,Spindle-Cell Carcinoma,Spindle-Cell Carcinomas,Tumor, Malignant Epithelial,Undifferentiated Carcinoma,Undifferentiated Carcinomas
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000609 Aminoacridines Acridines which are substituted in any position by one or more amino groups or substituted amino groups.
D000677 Amsacrine An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent. m-AMSA,AMSA,AMSA P-D,Amsacrina,Amsidine,Amsidyl,Cain's Acridine,NSC-141549,NSC-156303,NSC-249992,SN-11841,SN11841,meta-AMSA,AMSA P D,AMSA PD,Cain Acridine,Cains Acridine,NSC 141549,NSC 156303,NSC 249992,NSC141549,NSC156303,NSC249992,SN 11841,meta AMSA
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

E S Casper, and R J Gralla, and D P Kelsen, and R B Natale, and P Sordillo, and A Houghton
A phase II evaluation of m-AMSA, 4'-(9-acridinylamino) methanesulfon-m-anisidide, in patients with breast cancer.
January 1981, Cancer clinical trials,
E S Casper, and R J Gralla, and D P Kelsen, and R B Natale, and P Sordillo, and A Houghton
Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (m-AMSA) in patients with gastric adenocarcinoma.
June 1982, American journal of clinical oncology,
E S Casper, and R J Gralla, and D P Kelsen, and R B Natale, and P Sordillo, and A Houghton
Phase II. Evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA) in patients with advanced sarcoma.
January 1980, Cancer treatment reports,
E S Casper, and R J Gralla, and D P Kelsen, and R B Natale, and P Sordillo, and A Houghton
Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA) in patients with advanced colorectal carcinoma.
January 1980, Cancer treatment reports,
E S Casper, and R J Gralla, and D P Kelsen, and R B Natale, and P Sordillo, and A Houghton
Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in metastatic breast cancer.
January 1979, Cancer treatment reports,
E S Casper, and R J Gralla, and D P Kelsen, and R B Natale, and P Sordillo, and A Houghton
Phase II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with metastatic hypernephroma.
January 1980, Cancer treatment reports,
E S Casper, and R J Gralla, and D P Kelsen, and R B Natale, and P Sordillo, and A Houghton
Phase II evaluation of m-AMSA (4'-(9-acridinylamino)-methanesulfon-m-anisidide) in patients with adenocarcinoma of the pancreas.
August 1983, American journal of clinical oncology,
E S Casper, and R J Gralla, and D P Kelsen, and R B Natale, and P Sordillo, and A Houghton
Phase II study of 4'-(9-acridinylamino) methanesulfon-m- anisidide (AMSA) in metastatic melanoma.
January 1980, Cancer clinical trials,
E S Casper, and R J Gralla, and D P Kelsen, and R B Natale, and P Sordillo, and A Houghton
Phase II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with metastatic renal cell carcinoma.
January 1980, Cancer treatment reports,
E S Casper, and R J Gralla, and D P Kelsen, and R B Natale, and P Sordillo, and A Houghton
[Phase I-II studies of a new antineoplastic agent, 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA)].
February 1982, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!